Drugs/Recall·openFDA/drug

Guardian Drug Co. Inc. — Class II: HALEON CALCIUM CARBONATE TUMS ANTACID, Assorted Fruit Tablets, 1000 mg, 160-count bottle,

MediumPublished Jun 10, 2026· AI-analyzed Jun 15, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Guardian Drug Co. Inc. has initiated a Class II recall for Haleon Calcium Carbonate Tums Antacid (1000 mg, 160-count bottles) due to the presence of small metallic particles in the chewable tablets. The recall is currently listed as ongoing.

Who it affects

This recall affects the contract manufacturer (Guardian Drug Co. Inc.), the brand owner (Haleon), and professionals in quality control, manufacturing, and distribution of OTC antacid products.

Why it matters

The presence of foreign metallic substances suggests a potential failure in the manufacturing process or equipment integrity, such as metal-on-metal wear or screen breakage. While classified as Class II (suggesting a lower risk of permanent health consequences), the incident likely requires a thorough CAPA (Corrective and Preventive Action) investigation to identify the source of contamination and assess the effectiveness of in-line metal detection or physical screening protocols.

Practical takeaway

QA teams should review manufacturing logbooks for equipment wear or maintenance issues that could result in metal shedding. Supply chain and distribution departments should immediately verify inventory against the specified UPC (3 07660 74610 2) to ensure affected lots are quarantined.

FDA source material

Class II. Reason: Presence of foreign substance: small metallic particles in chewable tablets.. Product: HALEON CALCIUM CARBONATE TUMS ANTACID, Assorted Fruit Tablets, 1000 mg, 160-count bottle, Haleon, Warren, NJ 07059, UPC 3 07660 74610 2.. Firm: Guardian Drug Co. Inc. (Dayton NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.